ZA201306546B - C-17 and c-3 modified triterpenoids with hiv maturation inhibitory activity - Google Patents

C-17 and c-3 modified triterpenoids with hiv maturation inhibitory activity

Info

Publication number
ZA201306546B
ZA201306546B ZA2013/06546A ZA201306546A ZA201306546B ZA 201306546 B ZA201306546 B ZA 201306546B ZA 2013/06546 A ZA2013/06546 A ZA 2013/06546A ZA 201306546 A ZA201306546 A ZA 201306546A ZA 201306546 B ZA201306546 B ZA 201306546B
Authority
ZA
South Africa
Prior art keywords
inhibitory activity
hiv maturation
maturation inhibitory
modified triterpenoids
triterpenoids
Prior art date
Application number
ZA2013/06546A
Other languages
English (en)
Inventor
Alicia Regueiro-Ren
Jacob Swidorski
Brian Lee Venables
Ya Chen
Nicholas A Meanwell
Zheng Liu
Ny Sin
Sing-Yueng Sit
Jie Chen
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of ZA201306546B publication Critical patent/ZA201306546B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J63/00Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J63/00Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008Expansion of ring D by one atom, e.g. D homo steroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA2013/06546A 2011-01-31 2013-08-30 C-17 and c-3 modified triterpenoids with hiv maturation inhibitory activity ZA201306546B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161437893P 2011-01-31 2011-01-31
PCT/US2012/022852 WO2012106190A1 (en) 2011-01-31 2012-01-27 C-17 and c-3 modified triterpenoids with hiv maturation inhibitory activity

Publications (1)

Publication Number Publication Date
ZA201306546B true ZA201306546B (en) 2015-03-25

Family

ID=45567147

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2013/06546A ZA201306546B (en) 2011-01-31 2013-08-30 C-17 and c-3 modified triterpenoids with hiv maturation inhibitory activity

Country Status (25)

Country Link
US (3) US8846647B2 (enExample)
EP (1) EP2670765B1 (enExample)
JP (1) JP6001560B2 (enExample)
KR (1) KR101886467B1 (enExample)
CN (1) CN103429607B (enExample)
AR (1) AR085053A1 (enExample)
AU (1) AU2012212509B2 (enExample)
BR (1) BR112013019419A2 (enExample)
CA (1) CA2826113C (enExample)
CL (1) CL2013002185A1 (enExample)
CO (1) CO6751275A2 (enExample)
EA (1) EA022470B1 (enExample)
ES (1) ES2653847T3 (enExample)
IL (1) IL227678B (enExample)
MA (1) MA34909B1 (enExample)
MY (1) MY162186A (enExample)
PE (1) PE20141152A1 (enExample)
PH (1) PH12013501528A1 (enExample)
PT (1) PT2670765T (enExample)
SG (1) SG192144A1 (enExample)
TN (1) TN2013000321A1 (enExample)
TW (1) TWI628188B (enExample)
UY (1) UY33886A (enExample)
WO (1) WO2012106190A1 (enExample)
ZA (1) ZA201306546B (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE033288T2 (en) 2008-04-18 2017-11-28 Reata Pharmaceuticals Inc Antioxidant inflammation modulators: C-17 homologated oleic acid derivatives
CA2721665C (en) 2008-04-18 2017-01-24 Reata Pharmaceuticals, Inc. Compounds including an anti-inflammatory pharmacore and methods of use
WO2009129545A1 (en) 2008-04-18 2009-10-22 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the c-ring
KR101735807B1 (ko) 2008-04-18 2017-05-15 리타 파마슈티컬스 잉크. C-17에 아미노 및 기타 변형을 갖는 올레아놀산 유도체를 포함하는 항산화 염증 조절제
HUE038046T2 (hu) 2010-12-17 2018-09-28 Reata Pharmaceuticals Inc Antioxidáns gyulladáscsökkentõ pirazolil és pirimidinil triciklusos enonok
RS54352B1 (sr) * 2011-01-31 2016-02-29 Bristol-Myers Squibb Company C-28 amini c-3 modifikovanih derivata betulinske kiseline kao inhibitori sazrevanja hiv-a
CN103619866B (zh) 2011-03-11 2016-06-22 里亚塔医药公司 C4-一甲基三萜系化合物的衍生物及其使用方法
BR112014006559A2 (pt) 2011-09-21 2017-03-28 Bristol Myers Squibb Co derivados do ácido betulínico com atividade antiviral
US8906889B2 (en) * 2012-02-15 2014-12-09 Bristol-Myers Squibb Company C-3 cycloalkenyl triterpenoids with HIV maturation inhibitory activity
ME02926B (me) 2012-04-27 2018-04-20 Reata Pharmaceuticals Inc 2,2-difluoropropionamidni derivati bardoksolon metila, polimorfni oblici i postupci za njihovu upotrebu
US8889854B2 (en) * 2012-05-07 2014-11-18 Bristol-Myers Squibb Company C-17 bicyclic amines of triterpenoids with HIV maturation inhibitory activity
US9556222B2 (en) 2012-06-15 2017-01-31 Reata Pharmaceuticals, Inc. A-ring epoxidized triterpenoid-based anti-inflammation modulators and methods of use thereof
US9273001B2 (en) * 2012-08-15 2016-03-01 Glaxo Group Limited Chemical process
US9278912B2 (en) 2012-09-10 2016-03-08 Reata Pharmaceuticals, Inc. C13-hydroxy derivatives of oleanolic acid and methods of use thereof
CR20150117A (es) 2012-09-10 2016-10-10 Reata Pharmaceuticals Inc Derivados c17-alcandilo y alquendilo del ácido oleanólico y sus métodos de uso
US9512094B2 (en) 2012-09-10 2016-12-06 Reata Pharmaceuticals, Inc. C17-heteroaryl derivatives of oleanolic acid and methods of use thereof
SG11201505639SA (en) * 2013-02-06 2015-08-28 Bristol Myers Squibb Co C-19 modified triterpenoids with hiv maturation inhibitory activity
MX2015010354A (es) 2013-02-25 2015-10-09 Squibb Bristol Myers Co Derivados de acido betulinico modificados con aquilo c-3 y alquenilo utiles en el tratamiento de virus de inmunodeficiencia humana (vih).
PL3129392T3 (pl) 2014-04-11 2021-04-06 VIIV Healthcare UK(No.4) Limited Triterpenoidy o aktywności hamującej dojrzewanie hiv, podstawione w pozycji 3 niearomatycznym pierścieniem zawierającym podstawnik fluorowcoalkilowy
WO2015195776A1 (en) 2014-06-19 2015-12-23 Bristol-Myers Squibb Company Betulinic acid derivatives with hiv maturation inhibitory activity
US10047118B2 (en) 2014-11-14 2018-08-14 VIIV Healthcare UK (No.5) Limited C17-aryl substituted betulinic acid analogs
US9969767B2 (en) 2014-11-14 2018-05-15 VIIV Healthcare UK (No.5) Limited Oxolupene derivatives
US10221208B2 (en) 2015-04-14 2019-03-05 ViiV Healthcare UK (No.4) Limited Methods of producing an HIV maturation inhibitor
WO2017017609A1 (en) 2015-07-28 2017-02-02 Glaxosmithkline Intellectual Property (No.2) Limited Betuin derivatives for preventing or treating hiv infections
CA2993758A1 (en) 2015-07-28 2017-02-02 Glaxosmithkline Intellectual Property (No.2) Limited Betuin derivatives for preventing or treating hiv infections
WO2017025901A1 (en) * 2015-08-11 2017-02-16 Hetero Research Foundation Novel c28-analogues with c3-modifications of triterpene derivatives as hiv inhibitors
EA201890767A1 (ru) 2015-09-23 2019-09-30 Рита Фармасьютикалз, Инк. C4-модифицированные производные олеаноловой кислоты для ингибирования il-17 и других применений
AU2016327169A1 (en) 2015-09-24 2018-04-12 Glaxosmithkline Intellectual Property (No.2) Limited Compounds with hiv maturation inhibitory activity
RU2018116772A (ru) 2015-11-20 2019-12-20 ВАЙВ ХЕЛТКЕР ЮКей (N4) ЛИМИТЕД Композиции ингибитора созревания ВИЧ
EP3405474A1 (en) * 2016-01-20 2018-11-28 Glaxosmithkline Intellectual Property (No. 2) Limited Amine derivatives of lupanes with hiv maturation inhibitory activity
AR107512A1 (es) * 2016-02-04 2018-05-09 VIIV HEALTHCARE UK Nº 5 LTD Triterpenoides modificados en c-3 y c-17 como inhibidores del vih-1
WO2018002849A1 (en) * 2016-06-30 2018-01-04 VIIV Healthcare UK (No.5) Limited Triterpenoid inhibitors of human immunodeficiency virus replication
WO2018044822A1 (en) * 2016-08-31 2018-03-08 Viiv Healthcare Company Combinations and uses and treatments thereof
MX2020001412A (es) 2017-08-04 2020-08-03 Ardelyx Inc Compuestos y métodos para tratar la hiperpotasemia.
JP6926939B2 (ja) * 2017-10-23 2021-08-25 東京エレクトロン株式会社 半導体装置の製造方法
JP6977474B2 (ja) * 2017-10-23 2021-12-08 東京エレクトロン株式会社 半導体装置の製造方法
EP4321164A3 (en) 2018-04-24 2024-04-17 ViiV Healthcare UK (No.5) Limited Compounds with hiv maturation inhibitory activity
PL237998B1 (pl) 2018-05-28 2021-06-28 Narodowy Inst Lekow Fosfonowe pochodne kwasu 3-karboksyacylobetulinowego, sposób ich otrzymywania oraz ich zastosowanie
EP3810141A1 (en) 2018-06-20 2021-04-28 Reata Pharmaceuticals, Inc. Cysteine-dependent inverse agonists of nuclear receptors ror-gamma/ror-gamma-t and methods of treating diseases or disorders therewith
JP7735185B2 (ja) 2019-02-07 2025-09-08 アルデリックス, インコーポレイテッド 高カリウム血症の治療で使用するためのグリチルレチン酸誘導体
HRP20231582T1 (hr) 2019-02-11 2024-03-15 Hetero Labs Limited Novi derivati triterpena kao inhibitori hiv-a
KR102891865B1 (ko) 2019-07-19 2025-11-26 리아타 파마슈티컬즈, 아이엔씨. C17 극성-치환된 헤테로방향족 합성 트리터페노이드 및 그의 사용 방법
GB2598300A (en) * 2020-08-21 2022-03-02 Univ Durham Cross-linking method and applications in bioconjugation

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5413999A (en) 1991-11-08 1995-05-09 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
US5869535A (en) 1995-03-21 1999-02-09 The Board Of Trustees Of The University Of Illinois Method and composition for selectively inhibiting melanoma
US5962527A (en) 1995-03-21 1999-10-05 The Board Of Trustees Of The University Of Illinois Method and composition for treating cancers
US5679828A (en) 1995-06-05 1997-10-21 Biotech Research Labs, Inc. Betulinic acid and dihydrobetulinic acid derivatives and uses therefor
US20020137755A1 (en) 2000-12-04 2002-09-26 Bilodeau Mark T. Tyrosine kinase inhibitors
US20040110785A1 (en) 2001-02-02 2004-06-10 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
US7365221B2 (en) 2002-09-26 2008-04-29 Panacos Pharmaceuticals, Inc. Monoacylated betulin and dihydrobetulin derivatives, preparation thereof and use thereof
WO2004089357A2 (en) 2003-04-02 2004-10-21 Regents Of The University Of Minnesota Anti-fungal formulation of triterpene and essential oil
US7745625B2 (en) 2004-03-15 2010-06-29 Bristol-Myers Squibb Company Prodrugs of piperazine and substituted piperidine antiviral agents
MXPA06010592A (es) 2004-03-17 2007-06-12 Panacos Pharmaceuticals Inc Sales farmaceuticas de acido 3-o-(3',3'-dimetilsuccinil) betulinico.
TW200628161A (en) 2004-11-12 2006-08-16 Panacos Pharmaceuticals Inc Novel betulin derivatives, preparation thereof and use thereof
US8067620B2 (en) 2005-05-04 2011-11-29 Medicines For Malaria Venture Mmv Dispiro 1,2,4-trioxolane antimalarials
WO2008127364A2 (en) * 2006-10-13 2008-10-23 Myriad Genetics, Inc. Antiviral compounds and use thereof
US20110144069A1 (en) 2006-10-16 2011-06-16 Myriad Genetics, Incorporated Compounds for treating viral infections
EP2257567A1 (en) * 2008-02-14 2010-12-08 Virochem Pharma Inc. Novel 17 beta lupane derivatives
US9067966B2 (en) 2009-07-14 2015-06-30 Hetero Research Foundation, Hetero Drugs Ltd. Lupeol-type triterpene derivatives as antivirals
MX2012013628A (es) * 2010-06-04 2012-12-17 Bristol Myers Squibb Co Amidas c-28 de derivados del acido betulinico c-3 modificados como inhibidores de la maduracion del virus de inmunodeficiencia humana (vih).
CN103038245B (zh) * 2010-06-04 2015-03-25 百时美施贵宝公司 作为hiv成熟抑制剂的c-3经修饰的桦木酸衍生物

Also Published As

Publication number Publication date
KR20140016279A (ko) 2014-02-07
EP2670765A1 (en) 2013-12-11
TWI628188B (zh) 2018-07-01
PT2670765T (pt) 2018-01-08
MA34909B1 (fr) 2014-02-01
MY162186A (en) 2017-05-31
CN103429607A (zh) 2013-12-04
CA2826113A1 (en) 2012-08-09
PE20141152A1 (es) 2014-09-22
CO6751275A2 (es) 2013-09-16
SG192144A1 (en) 2013-08-30
CN103429607B (zh) 2016-02-17
IL227678A0 (en) 2013-09-30
US20140343000A1 (en) 2014-11-20
EA022470B1 (ru) 2016-01-29
ES2653847T3 (es) 2018-02-09
NZ614871A (en) 2014-06-27
CA2826113C (en) 2018-09-04
AU2012212509A1 (en) 2013-09-19
EP2670765B1 (en) 2017-10-18
JP6001560B2 (ja) 2016-10-05
UY33886A (es) 2012-07-31
TW201309717A (zh) 2013-03-01
TN2013000321A1 (en) 2015-01-20
IL227678B (en) 2018-04-30
AU2012212509B2 (en) 2016-01-21
PH12013501528A1 (en) 2013-09-16
JP2014503595A (ja) 2014-02-13
BR112013019419A2 (pt) 2019-12-03
AR085053A1 (es) 2013-08-07
US8846647B2 (en) 2014-09-30
US20160151387A1 (en) 2016-06-02
WO2012106190A1 (en) 2012-08-09
US20130035318A1 (en) 2013-02-07
KR101886467B1 (ko) 2018-08-07
CL2013002185A1 (es) 2013-12-27
EA201391127A1 (ru) 2013-12-30

Similar Documents

Publication Publication Date Title
ZA201306546B (en) C-17 and c-3 modified triterpenoids with hiv maturation inhibitory activity
IL234077A (en) C3-Cycloalkanyl tritrapenoids with antioxidant activity of HIV
IL253818A0 (en) Structured cutting operation to create chips
SI2683731T1 (sl) C4-monometil triterpenoidni derivati in postopki njihove uporabe
PL2686331T3 (pl) Rebaudiozyd b i pochodne
EP2717931A4 (en) ASSOCIATIONS AND RELATED METHODS
AP4055A (en) Dihydro-benzo-oxazine and dihydro-pyrido-oxazine derivatives
ZA201405819B (en) Lupane triterpenoid derivatives and pharmaceutical use thereof
IL235465A (en) Biocyclic amines in position c-17 of tritrapenoids as maturation inhibitors of HIV virus
ZA201405085B (en) Construction panel and manufacture thereof
IL216345A0 (en) Wing and devices therefor
IL231541A0 (en) Conjugates containing steroids from plants and their use
EP2716359A4 (en) COMPLEX AND USES THEREOF
EP2712348A4 (en) DISTRIBUTOR AND METHODS
HK1191017A (en) C-17 and c-3 modified triterpenoids with hiv maturation inhibitory activity
PL2688418T3 (pl) Bogata w stygmasterol kompozycja fitosterolowa i jej zastosowania
HK1191247A (en) Combination comprising umeclidinium and a corticosteroid
GB201107656D0 (en) Short back and sides
GB201119443D0 (en) GoWinging Concept and patent
IL230826A0 (en) Structured cutting operation to create chips
GB201118317D0 (en) Intrathermic and interthermic extractive thermiats
AU2011900677A0 (en) Therapeutic and diagnostic agents
GB201102208D0 (en) Inventions and therapy
GB201102210D0 (en) Inventions and therapy